Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

This study has been completed.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Richard Thomas Penson, Massachusetts General Hospital Identifier:
First received: September 8, 2005
Last updated: March 27, 2017
Last verified: March 2017
Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma. This study looks at ability of GM-CSF to alter disease progression in women who have recurrent but asymptomatic recurrence of their ovarian cancer.

Condition Intervention Phase
Ovarian Cancer
Fallopian Tube Cancer
Drug: GM-CSF, sargramostim
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Phase II Trial of GM-CSF in Women With Asymptomatic Ovarian, Primary Peritoneal, or Tubal Carcinoma

Resource links provided by NLM:

Further study details as provided by Richard Thomas Penson, Massachusetts General Hospital:

Primary Outcome Measures:
  • Median Time to Treatment Termination (TTT) [ Time Frame: Up to 460 days ]
    TTT is the median time in days to discontinuing treatment with GM-CSF, sargramostim (treatment termination) e.g. time on study until progression of disease, unacceptable adverse effects, bowel obstruction, development of new ascites or pleural effusions, initiation of systemic chemotherapy, participant death, development of co-morbid diseases which make participant continuation on the trial unsafe in the judgment of the principal investigator or the treating physician or withdrawal of consent by the participant.

Secondary Outcome Measures:
  • Median Time to Progression (TTP) [ Time Frame: Up to 60 months ]
    TTP was defined as the median time in days from trial entry until progressive disease (PD) was documented as defined by RECIST criteria. PD was defined of at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In participants with no measurable disease who had an informative cancer antigen-125 (CA-125), PD was defined as a rise of > 50% over Baseline, confirmed by a subsequently higher value at least 21 days later.

  • Tumor Response Rate (RR) [ Time Frame: Up to 60 months ]
    RR is the percentage of patients with response as assessed by the investigator using Response Evaluable Criteria in Solid Tumors (RECIST) and CA-125 Rustin criteria. Complete Response (CR) is the disappearance of all target and non-target lesions and normalization of CA-125. Partial Response (PR) is at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD; in patients with no measurable disease with an informative CA-125, the 75% definitions by Rustin is used. Stable Disease is neither sufficient shrinkage for PR nor increase for PD, taking as reference the smallest sum LD since the treatment start. PD is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment start or the appearance of one or more new lesions; in patients with no measurable disease with an informative CA-125, PD is defined as a rise of > 50% over baseline, confirmed by a higher value 21 days later.

  • Number of Participants With Adverse Events (Toxicity) Grade 3 or 4 [ Time Frame: Up to 460 days ]
    Adverse Events (previously toxicity) were graded according the National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 3.0. The total number of participants with adverse events graded 3 (severe) or 4 (life-threatening or disabling) are reported.

Other Outcome Measures:
  • Change From Baseline of Anti-Trag Antibodies [ Time Frame: Up to 60 months ]

Enrollment: 72
Study Start Date: December 2004
Study Completion Date: April 2010
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GM-CSF, Sargramostim Cohort 1
GM-CSF, Sargramostim 250 μg/m^2 subcutaneous injection daily on days 1 to 14 in a 28-day cycle until disease progression or unacceptable toxicity for a median of 3 cycles.
Drug: GM-CSF, sargramostim
GM-CSF subcutaneous injection
Other Name: Leukine®
Experimental: GM-CSF, Sargramostim Cohort 2
GM-CSF, sargramostim 150 μg/m^2 subcutaneous injection daily for 28 days in a 28-day cycle until disease progression or unacceptable toxicity fora median of 3 cycles. GM-CSF, sargramostim dose escalation was permitted up to 250 μg/m^2 per day if applicable based on toxicity and white blood cell count.
Drug: GM-CSF, sargramostim
GM-CSF subcutaneous injection
Other Name: Leukine®

Detailed Description:
This is an open labeled, single arm phase II study of GM-CSF, sargramostim delivered daily without a break in a population of healthy and fit women with evidence of recurrent but asymptomatic mullerian malignancy (such as ovarian cancer, fallopian tube cancer, or primary peritoneal cancer). The main goal is to determine the time to treatment termination due to disease progression or toxicity.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have a history of histologic or cytologic diagnosis of primary ovarian, primary peritoneal or tubal carcinoma.
  • Patients must be asymptomatic from their cancer.
  • Patients must have evidence of recurrent carcinoma, as determined by:

    • A rising cancer antigen 125 (CA-125) serum level greater than 35 U/mL or two successive rising values with the most recent value at least 3 times the nadir value.
    • Or evidence of evaluable or measurable disease by x-ray or computed tomography (CT) scan.
  • Patients may not receive concurrent antineoplastic therapy. All hormonal therapy used as a treatment modality (i.e. tamoxifen, arimidex, etc) must be stopped prior to treatment on protocol.
  • Age > 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status < 2.

Exclusion Criteria:

  • Known severe hypersensitivity to GM-CSF.
  • Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or concurrent superficial or stage IB endometrial carcinoma.
  • Concomitant use of anti-neoplastic therapy.
  • Treatment with a non-FDA approved or investigational drug within 30 days before Day 1 of trial treatment.
  • Any unresolved chronic toxicity greater then Common Toxicity Criteria (CTC) grade 2 from previous anticancer therapy (except alopecia).
  • Serum creatinine level greater than CTC grade 2 [1.5 x upper limit normal (ULN)].
  • Pregnancy or breast feeding (women of childbearing potential).
  • Severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) as judged by the investigator.
  • Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate in the trial as judged by the investigator.
  • Patients currently receiving other investigational antineoplastic agents, on systemic chemotherapy or under radiation therapy treatment.
  • Patients with clinical and/or radiographic evidence of current or impending bowel obstruction.
  • Performance status < 1.
  • Ability to understand and the willingness to sign a written informed consent document.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00157573

Sponsors and Collaborators
Massachusetts General Hospital
Dana-Farber Cancer Institute
Principal Investigator: Richard T Penson, M.D. Massachusetts General Hospital
  More Information

Additional Information:
Responsible Party: Richard Thomas Penson, MD, Massachusetts General Hospital Identifier: NCT00157573     History of Changes
Other Study ID Numbers: 04-305
Study First Received: September 8, 2005
Results First Received: April 23, 2013
Last Updated: March 27, 2017

Keywords provided by Richard Thomas Penson, Massachusetts General Hospital:
Clinical trial
Phase II

Additional relevant MeSH terms:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Fallopian Tube Diseases processed this record on May 25, 2017